ArticleAmerican heart journal2025

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial.

Nancy Haff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.